Sugi Predict

Sugi Predict / Compounds / SCHEMBL155127

SCHEMBL155127

SCHEMBL155127

O=[N+]([O-])c1ccc2ncnc(Cl)c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 4/20 0.56
▸ KDR P35968 1/20 0.56
▸ ALK Q9UM73 1/20 0.53
▸ PARP1 P09874 1/20 0.53
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ ALDH1A1 P00352 3/20 0.48
▸ MAPT P10636 3/20 0.48
▸ HTT P42858 3/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ OPRK1 P41145 1/20 0.48
▸ IRAK4 Q9NWZ3 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ NCOA1 Q15788 1/20 0.47
▸ NCOA3 Q9Y6Q9 1/20 0.47
▸ CYP3A4 P08684 1/20 0.46
▸ NAMPT P43490 1/20 0.46
▸ XDH P47989 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ PDE4A P27815 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2250729 0.98 EGFR (0.55) EGFRKDRALKPARP1L3MBTL1
Sulfurous Acid SCHEMBL28743416 0.93 EGFR (0.50) EGFRKDRALKPARP1L3MBTL1
Sulfurous Acid SCHEMBL28743417 0.91 ALK (0.50) EGFRKDRALKPARP1L3MBTL1
Sulfurous Acid SCHEMBL28743415 0.90 ALK (0.49) EGFRKDRALKPARP1L3MBTL1
SCHEMBL29873053 0.87 EGFR (0.56) EGFRKDRALKALDH1A1MAPT
SCHEMBL1438134 0.87 EGFR (0.56) EGFRKDRALKALDH1A1MAPT
Hydrochloric Acid SCHEMBL7209642 0.85 EGFR (0.55) EGFRKDRALKALDH1A1MAPT
SCHEMBL27739841 0.83 EGFR (0.51) EGFRKDRL3MBTL1ALDH1A1MAPT
SCHEMBL1192812 0.80 ALK (0.60) EGFRKDRALKPARP1L3MBTL1
SCHEMBL28813506 0.80 EGFR (0.56) EGFRKDRALKPARP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112209875-B 6-amino-4- (4-phenoxyphenethylamino) quinazoline derivative and preparation method and application thereof 绍兴文理学院 2021-11-30 — — CN claimed
CN-112209875-A 6-amino-4- (4-phenoxyphenethylamino) quinazoline derivative and preparation method and application thereof 绍兴文理学院 2021-01-12 — — CN claimed
CN-106432205-A Method for synthesizing lapatinib or intermediate thereof 成都美睿科生物科技有限公司 2017-02-22 — — CN claimed
CN-103275018-B 4-[the chloro-4-substituted anilinic of 3-]-6-substituted formyl amino-quinazoline compound and Synthesis and applications JIANG University OF TECHNOLOGY (CN) 2016-03-02 — — CN claimed
CN-103275019-A 4-(3-chloro-4-substituted anilino)-6-substituted methoxyl carbamonyl quinazoline compounds, and a preparation method and applications thereof UNIV ZHEJIANG TECHNOLOGY 2013-09-04 — — CN claimed
CN-103275018-A 4-(3-chloro-4-substituted anilino)-6-substituted carbamonyl quinazoline compounds, and preparation method and applications thereof UNIV ZHEJIANG TECHNOLOGY 2013-09-04 — — CN claimed
CN-103254143-A 4-[4-(2-diethylamino acetamido)phenylamino]-6-(substituted methoxyl)formylamino quinazoline compound as well as preparation method and application thereof UNIV ZHEJIANG TECHNOLOGY 2013-08-21 — — CN claimed
CN-103254141-A 4-[4-(2-dipropylamino acetamido) phenylamino]-6-substituted quinazoline compound as well as preparation method and application thereof UNIV ZHEJIANG TECHNOLOGY 2013-08-21 — — CN claimed
CN-101665466-B Preparation method of quinazoline disulfide tetroxide derivative JIANGSU INST NUCLEAR MEDICINE 2011-06-15 — — CN claimed
CN-101665466-A Preparation method of quinazoline disulfide tetroxide derivative JIANGSU INST OF NUCLEAR MED 2010-03-10 — — CN claimed
US-20250213571-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. 2025-07-03 — — US disclosed
EP-4547253-A1 PROCESS FOR THE PREPARATION OF TUCATINIB Dr. Reddy's Laboratories Limited (IN) 2025-05-07 — — EP disclosed
EP-4493562-A1 TYK2 INHIBITORS AND USES THEREOF Alumis Inc. (US) 2025-01-22 — — EP disclosed
US-12171739-B2 N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases ARRAY BIOPHARMA INC. (US) 2024-12-24 — — US disclosed
CN-114773278-B Quinazoline compound and application thereof in antiviral 苏州大学 2024-07-30 — — CN disclosed
US-5457105-A anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) ZENECA LIMITED (GB) 1995-10-10 — — US disclosed
CN-1094043-A Quinazoline derivant ZENECA LTD (GB) 1994-10-26 — — CN disclosed
EP-0602851-A1 Quinazoline derivatives ZENECA LIMITED (GB) 1994-06-22 — — EP disclosed
EP-0566226-A1 Quinazoline derivatives ZENECA LIMITED (GB) 1993-10-20 — — EP disclosed
EP-0520722-A1 Therapeutic preparations containing quinazoline derivatives ZENECA LIMITED (GB) 1992-12-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213571-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK1, JAK2 EGFR 944/4885KDR 2598/4885ALK 914/4885
US-12171739-B2 N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases ERBB4, ERBB2, ERBB3 EGFR 4/4885KDR 71/4885ALK 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.